Myriad to Present New Data from Its Industry-Leading Portfolio of Genetic Tests for Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Myriad Genetics, Inc. (MYGN)
Last myriad genetics, inc. earnings: 2/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
myriad.com/news-center/investor-information
Company Research
Source: GlobeNewswire
SALT LAKE CITY, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that 10 studies will be featured at the San Antonio Breast Cancer Symposium (SABCS) being held Dec. 4-8, 2018 in San Antonio, Tx. Data from four Myriad products will be featured including myRisk® Hereditary Cancer, riskScore™, EndoPredict®, and myChoice HRD™."More than 3 million American women have breast cancer, and there is critical need to transform the standard of care and improve outcomes for these patients," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetics. "We are excited to be presenting new data across multiple genetic tests at SABCS and to highlight our progress in advancing precision medicine for women with breast cancer.”Please visit Myriad at Booth #1001 to learn more about genetic testing for breast cancer. Follow Myriad on Twitter via @myriadgenetics and keep up to date with Symposium news and
Show less
Read more
Impact Snapshot
Event Time:
MYGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MYGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MYGN alerts
High impacting Myriad Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
MYGN
News
- The Former Director Of The NIH Shared His Prostate Cancer Journey. Use His Story To Reduce Your Risk Of Dying Of This Disease. [Forbes]Forbes
- Nearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor [Yahoo! Finance]Yahoo! Finance
- Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health MonitorGlobeNewswire
- New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen [Yahoo! Finance]Yahoo! Finance
- New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal ScreenGlobeNewswire
MYGN
Earnings
- 2/27/24 - Beat
MYGN
Sec Filings
- 4/17/24 - Form ARS
- 4/17/24 - Form DEFA14A
- 4/17/24 - Form DEF
- MYGN's page on the SEC website